ReviewJournal of clinical medicine2021
Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Effect of accelerated rehabilitation combined with enteral nutrition on gastrointestinal function recovery after hepatectomy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines.Cancer cell international · 2026Review
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression.World journal of gastrointestinal oncology · 2025Article
- FOLFOX-HAIC combined with PD-1 inhibitor immunotherapy significantly improves survival in patients with advanced hepatocellular carcinoma.American journal of translational research · 2025Article
- TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.Cancer science · 2024Article
- Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review.Cancer cell international · 2024Review
- Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC).Journal of translational medicine · 2023Review
- Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma.Pharmaceutics · 2023Review
- Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.Materials today. Bio · 2022Article
- Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.Biomarker research · 2021Review
- Review
- Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.